Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtTEnd – Atezolizumab Trial in Endometrial Cancer
KCT0005761Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in endometrial cancer (EC), Endometrial Sarcoma (ESS), sponsored by Mario Negri Institute for Pharmacological Research. Started Jun 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
endometrial cancer (EC)Endometrial Sarcoma (ESS)
Beyond the preview
Go deeper on KCT0005761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005761.